These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 21789012)
41. The impact of hormone therapy on post-implant dosimetry and outcome following Iodine-125 implant monotherapy for localised prostate cancer. Ash D; Al-Qaisieh B; Bottomley D; Carey B; Joseph J Radiother Oncol; 2005 Jun; 75(3):303-6. PubMed ID: 15890423 [TBL] [Abstract][Full Text] [Related]
42. Impact of race on biochemical disease recurrence after prostate brachytherapy. Yamoah K; Stone N; Stock R Cancer; 2011 Dec; 117(24):5589-600. PubMed ID: 21692058 [TBL] [Abstract][Full Text] [Related]
43. Five-year outcomes after iodine-125 seed brachytherapy for low-risk prostate cancer at three cancer centres in the UK. Dickinson PD; Malik J; Mandall P; Swindell R; Bottomley D; Hoskin P; Logue JP; Wylie JP BJU Int; 2014 May; 113(5):748-53. PubMed ID: 24053230 [TBL] [Abstract][Full Text] [Related]
44. Intermediate term biochemical-free progression and local control following 125iodine brachytherapy for prostate cancer. Stone NN; Stock RG; Unger P J Urol; 2005 Mar; 173(3):803-7. PubMed ID: 15711273 [TBL] [Abstract][Full Text] [Related]
45. Comparison of the 5-year outcome and morbidity of three-dimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early-stage prostatic cancer. Zelefsky MJ; Wallner KE; Ling CC; Raben A; Hollister T; Wolfe T; Grann A; Gaudin P; Fuks Z; Leibel SA J Clin Oncol; 1999 Feb; 17(2):517-22. PubMed ID: 10080594 [TBL] [Abstract][Full Text] [Related]
46. Does hormonal manipulation in conjunction with permanent interstitial brachytherapy, with or without supplemental external beam irradiation, improve the biochemical outcome for men with intermediate or high-risk prostate cancer? Merrick GS; Butler WM; Galbreath RW; Lief JH; Adamovich E BJU Int; 2003 Jan; 91(1):23-9. PubMed ID: 12614244 [TBL] [Abstract][Full Text] [Related]
47. Outcomes following iodine-125 monotherapy for localized prostate cancer: the results of leeds 10-year single-center brachytherapy experience. Henry AM; Al-Qaisieh B; Gould K; Bownes P; Smith J; Carey B; Bottomley D; Ash D Int J Radiat Oncol Biol Phys; 2010 Jan; 76(1):50-6. PubMed ID: 20005453 [TBL] [Abstract][Full Text] [Related]
48. Long-Term Prostate Specific Antigen Stability and Predictive Factors of Failure after Permanent Seed Prostate Brachytherapy. Tetreault-Laflamme A; Crook J; Hamm J; Pickles T; Keyes M; McKenzie M; Pai H; Bachand F; Morris J J Urol; 2018 Jan; 199(1):120-125. PubMed ID: 28827105 [TBL] [Abstract][Full Text] [Related]
49. Biochemical outcome for hormone-naive patients with Gleason score 3+4 versus 4+3 prostate cancer undergoing permanent prostate brachytherapy. Merrick GS; Butler WM; Galbreath RW; Lief JH; Adamovich E Urology; 2002 Jul; 60(1):98-103. PubMed ID: 12100932 [TBL] [Abstract][Full Text] [Related]
50. Prostate-specific antigen kinetics after I125-brachytherapy for prostate adenocarcinoma. Guarneri A; Botticella A; Ragona R; Filippi AR; Munoz F; Casetta G; Gontero P; Tizzani A; Ricardi U World J Urol; 2013 Apr; 31(2):411-5. PubMed ID: 22922810 [TBL] [Abstract][Full Text] [Related]
51. Biochemical outcome for hormone-naïve patients with high-risk prostate cancer managed with permanent interstitial brachytherapy and supplemental external-beam radiation. Merrick GS; Butler WM; Lief JH; Galbreath RW; Adamovich E Cancer J; 2002; 8(4):322-7. PubMed ID: 12184410 [TBL] [Abstract][Full Text] [Related]
52. Morbidity and prostate-specific antigen control of external beam radiation therapy plus low-dose-rate brachytherapy boost for low, intermediate, and high-risk prostate cancer. Koontz BF; Chino J; Lee WR; Hahn CA; Buckley N; Huang S; Kim J; Reagan R; Joyner R; Anscher MS Brachytherapy; 2009; 8(2):191-196. PubMed ID: 19433320 [TBL] [Abstract][Full Text] [Related]
53. The effect of isotope selection on the prostate-specific antigen response in patients treated with permanent prostate brachytherapy. Potters L; Huang D; Fearn P; Kattan MW Brachytherapy; 2003; 2(1):26-31. PubMed ID: 15062160 [TBL] [Abstract][Full Text] [Related]
54. Five-year biochemical outcome and toxicity with transperineal CT-planned permanent I-125 prostate implantation for patients with localized prostate cancer. Zelefsky MJ; Hollister T; Raben A; Matthews S; Wallner KE Int J Radiat Oncol Biol Phys; 2000 Jul; 47(5):1261-6. PubMed ID: 10889379 [TBL] [Abstract][Full Text] [Related]
55. High-risk prostate cancer with Gleason score 8-10 and PSA level ≤15 ng/mL treated with permanent interstitial brachytherapy. Fang LC; Merrick GS; Butler WM; Galbreath RW; Murray BC; Reed JL; Adamovich E; Wallner KE Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):992-6. PubMed ID: 20932674 [TBL] [Abstract][Full Text] [Related]
56. Prostate specific antigen findings and biopsy results following interactive ultrasound guided transperineal brachytherapy for early stage prostate carcinoma. Stock RG; Stone NN; DeWyngaert JK; Lavagnini P; Unger PD Cancer; 1996 Jun; 77(11):2386-92. PubMed ID: 8635111 [TBL] [Abstract][Full Text] [Related]
57. Outcomes following iodine-125 prostate brachytherapy with or without neoadjuvant androgen deprivation. Ohashi T; Yorozu A; Saito S; Momma T; Toya K; Nishiyama T; Yamashita S; Shiraishi Y; Shigematsu N Radiother Oncol; 2013 Nov; 109(2):241-5. PubMed ID: 24183866 [TBL] [Abstract][Full Text] [Related]
58. Biochemical disease-free survival rates following definitive low-dose-rate prostate brachytherapy with dose escalation to biologic target volumes identified with SPECT/CT capromab pendetide. Ellis RJ; Zhou H; Kim EY; Fu P; Kaminsky DA; Sodee B; Colussi V; Vance WZ; Spirnak JP; Kim C; Resnick MI Brachytherapy; 2007; 6(1):16-25. PubMed ID: 17284381 [TBL] [Abstract][Full Text] [Related]